Artivila Biopharma, Founded by Ex-Pfizer Chief Scientist, Secures Over RMB 100 Million in Series A Funding Ahead of IPO Filing

Jun 25, 2026 18:25 CST Updated 18:25

Artivila

Innovative Drug Developer

Recently,Artivila(Artivila Biopharma)Announced the recent successful completion ofRecentin hundred million yuanAWheelFinancing.

This round of financing was led by Sinopharm Capital, with follow-on investments from Junyi Investment and others.

The proceeds from this round of financing will be primarily used to strengthen the R&D platform and product pipeline development, corporate operations, and international business expansion, particularly focusing on the clinical development of core pipelines, indication expansion, andINDDeclaration, for the future'sIPO(Initial Public Offering) filing preparation.

Thus,Artivila CumulativeFinancing amount near4100 million yuan, fully reflecting the capital market’s high recognition of the competitiveness of the company’s platform and innovative drug pipeline, as well as its long-term growth potential, thereby supporting the achievement of its long-term strategic objectives.

Artivila is a biopharmaceutical company dedicated to empowering innovative drug discovery and development through its AI platform, founded by two top-tier drug hunters.

Dr. Zhendong Zhu, Founder and ChairmanWith over 20 years of experience in computer-aided drug discovery and development, previously served as Chief Scientist at Pfizer, deeply involved in multiple new drug R&D projects that advanced to clinical stages.

Co-founder Dr. Deqiang Niuwith many years of deep expertise in drug R&D,Formerly served as Vice President at Silicon Therapeutics, Director of Chemistry at Celgene, and as a Medicinal Chemistry Expert and Associate Director of Chemistry at Biogen, Enanta Pharmaceuticals, and Avila Therapeutics. Possesses over 20 years of experience in drug research and development, and holds more than 60 U.S. and PCT patents.

The company leverages an AI-driven drug discovery engine to focus on the development of First-in-Class and Best-in-Class pipelines in three high-value disease areas: autoimmune diseases, neurodegenerative diseases, and malignant tumors.

Public information shows that,Artivila's newly developed novel-target therapy for autoimmune diseasesSmall-molecule chemicalsClass 1 New Drug ARD-885Successfully Completed HealthSubjectPhase I Clinical TrialResearch.

AsThe first simultaneousTargetedIRAK4andIRAK1'sDual-targetSmall MoleculesClass 1 Novel Autoimmune Drug, ARD-885 Shows PromiseForImmune-related conditions such as rheumatoid arthritis and systemic lupus erythematosus/Inflammatory DiseasesThe patient provides aBrand NewTreatment Strategy。

In addition, Artivila will actively expand its global partnership network, strengthen collaboration with multinational pharmaceutical companies and clinical research institutions, leverage capital and industry resources to promote the internationalization of its products, and lay the foundation for futureIPOLay a solid foundation, ultimately achievingAIEmpowering the R&D of innovative drugs and delivering benefits to patients worldwide as our corporate mission.

—The End—

Recommended Reading